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Introduction
Approximately 30% of breast cancer patients carry PIK3CA
(phosphatidylinositol-4, 5-bisphosphate 3-kinase, catalytic subunit alpha) mutations (1-6). More than 90% of the PIK3CA mutations in breast cancers occur in three hotspots of the PIK3CA gene: E542 and E545 in the helical domain (exon9) and H1047 in the kinase domain (exon20) (2, (7) (8) (9) (10) (11) . All three hotspot mutations are oncogenic and constitutively activate the PI3K pathway (3, (12) (13) (14) (15) (16) (17) (18) (19) (20) . The remaining mutations are distributed over the entire PIK3CA coding sequence.
The role of PIK3CA mutations in breast cancer survival is controversial (21-31).
Many studies suggested that PIK3CA mutations are associated with favorable survival (21-26), others found that PIK3CA mutations are associated with worse outcomes (27, 28) ; and a number of studies found no association between PIK3CA mutations and breast cancer survival (29-31).
Recent in vitro studies suggested that tumor cells with an activated PI3K pathway are less sensitive to chemotherapy agents (32, 33) . However, few studies have investigated the association between PIK3CA mutations and the response to neoadjuvant chemotherapy in breast cancer (19, 34, 35) . Therefore, whether breast cancer patients with PIK3CA mutations are sensitive to neoadjuvant chemotherapy is not fully determined.
In the current study, the primary objective was to investigate the association Author Manuscript Published OnlineFirst on May 15, 2015; DOI: 10.1158/1078-0432.CCR- between PIK3CA mutations and the response to neoadjuvant chemotherapy in operable primary breast cancer patients who received neoadjuvant chemotherapy (n=729); and to explore the association between the PIK3CA mutations and survival in this cohort. The second objective was to identify the PIK3CA mutations in breast cancer tissues before and after neoadjuvant chemotherapy in a subgroup of patients (n=102) in this cohort and to investigate whether changes in PIK3CA mutations during treatment influenced the clinical outcome of this subgroup.
Patients and Methods

Study population
Fresh breast cancer tissues obtained from a 14-gauge core-needle biopsy prior to neoadjuvant chemotherapy were available for 774 operable primary breast cancer patients (stage I-III) who received neoadjuvant chemotherapy at the Breast Center, Peking University Cancer Hospital from May 2004 to May 2011. PIK3CA mutations were successfully identified in fresh cancer tissues that were taken before neoadjuvant chemotherapy in 729 of 774 patients (94.2%). Of these 729 patients, breast cancer tissues were also available for 102 patients after neoadjuvant chemotherapy, and PIK3CA mutations were successfully identified in these 102 patients.
The patients' ages at diagnosis ranged from 25 to 73 years, with a median of 49 years. The tumors were graded according to the modified Bloom-Richardson system. 
PIK3CA Mutation Analysis
Total RNA was extracted from breast tumor tissues obtained from a core-needle biopsy prior to neoadjuvant chemotherapy or taken following surgery using Trizol reagent (Life Technologies Inc., Gaithersburg, MD, USA) according to the manufacturer's instructions. In brief, 500 ng of RNA was transcribed to cDNA by a reverse transcriptase in a total of 20 μl RT reaction solution containing 4.0μl 5× first strand buffer, 10 mM DTT, 20U RNase inhibitor, 1 mM dNTP, 400ng random primer and 200 U superscript II reverse transcriptase (Invitrogen, UK). The resulting cDNA was subjected to PCR amplification. Mutational analysis of PIK3CA was performed using a set of 8 primer pairs (Supplementary Table S1 ) that covered the entire coding region of the PIK3CA gene. All fragments were sequenced using the BigDye Terminator Cycle Sequencing Kit and ABI3730 automated sequencer (Applied Biosystems, FosterCity, CA, USA). Each mutation was confirmed in duplicate.
Research. 
Pathology
Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) statuses were determined using the breast cancer tissues obtained from the core-needle biopsy using an immunohistochemical (IHC) assay as described previously (36) . ER or PR was considered positive when ≥1% of tumor cells showed positive nuclear staining. HER2 positivity was defined as a score of 3+ (IHC) or by HER2 gene amplification (fluorescence in situ hybridization). In this study, the breast cancer subgroups were classified according to ER, PR, HER2 statuses: luminal (ER+ and/or PR+, HER2-), HER2 (+), and triple-negative (TN, ER-/PR-/HER2-) (30).
Treatment
All the 729 patients received neoadjuvant chemotherapy, and 93% received 4 -8 cycles. Treatments were categorized into four subgroups as follows:
(1) 265 patients received anthracycline based regimens. Of these, 184 patients received a CTF (5-fluorouracil, pirarubicin, and cyclophosphamide) regimen, the details of which are described previously (36) ; 56 patients received the FEC regimen, epirubicin 90-100 mg/m 2 on day 1, every 3 weeks, the doses of 5-fluorouracil and cyclophosphamide were identical to the CTF regimen; 23 patients received the CAF regimen; 1 patient received pirarubicin plus cyclophosphamide regimen; and 1 patient received the AC regimen.
Statistical Analysis
The associations between PIK3CA mutations and clinicopathological characteristics or pCR rate were performed using the Pearson's χ 2 test or the Fisher exact test. For the survival analyses, disease-free survival (DFS) was defined as the time from date of diagnosis to first recurrence (local or distant), the contralateral breast cancer, or death from breast cancer without a recorded relapse. Distant disease-free survival (DDFS) was defined as the time from the date of diagnosis to either the first distant recurrence or death for which breast cancer was the primary or underlying cause. Survival was estimated using the Kaplan-Meier product-limit method and differences were tested for statistical significance using the log-rank test.
Cox proportional hazards regression models were used to test the prognostic role of the PIK3CA mutation status (Hazard ratios [HR] and 95% confidence intervals [CI]).
Two-sided P values less than 0.05 were considered to be statistically significant. All analyses were performed using the SPSS Statistics 20.0 software (Chicago, USA).
Results
The frequency of PIK3CA mutations
Of these patients, 28.3% (206/729) had PIK3CA mutations. The frequencies of PIK3CA mutations in the luminal, HER2 (+), and triple-negative (TN) subgroups were 30.6%, 27.5%, 22.7%, respectively (P=0.22) (Supplementary Table S2 ).
PIK3CA mutant than wild-type were more likely to be ER-and PR-positive (ER:
Research. P=0.034; PR: P=0.007, respectively), and no significant association was found between PIK3CA mutations and other clinicopathological characteristics (Table 1) .
Six patients contained two PIK3CA mutations, therefore, 212 PIK3CA mutations were found in the 206 patients. Of these 212 mutations, 87.3% (185 of 212) clustered in the three hotspots (E542/E545and H1047), and 12.7% (27 of 212) clustered in non-hotspots.
Response to Neoadjuvant Chemotherapy
In total, 19.5% of patients (142/729) achieved a pCR after neoadjuvant chemotherapy. Patients with PIK3CA mutations had a lower pCR rate than did those with wild-type (pCR rate, 14.6% v 21.4%, P=0.035) ( Fig. S1 ). When the pCR includes both breast and axillary lymph nodes, PIK3CA mutations were associated with lower pCR rate in the entire study cohort (mutant vs wild-type, 13.6% v 18.2%, P=0.14), although the difference did not reach a significance.
Among patients treated with anthracycline-based regimens (n=265), patients with PIK3CA mutations had a lower pCR rate than those with wild-type (14.1% v 19.4%, P=0.33) ( Table 3) ; among patients treated with anthracyclin-taxane based regimens (n=317), patients with PIK3CA mutations had a significantly lower pCR rate than those with wild-type (11.7% v 24.7%, P=0.009) ( Table 3) ; among patients treated with taxane-based regimen (n=100), the pCR rate was similar in patients with or without PIK3CA mutations (16.1% v 18.8%, P=0.74) ( Table 3 ).
In the luminal subgroup (n=376), patients with PIK3CA mutations had a lower pCR rate than those with wild-type (6.1% v 13.0%, P=0.047) (Supplementary Table   S6 ). In the TN subgroup (n=128), patients with PIK3CA mutations had a lower pCR rate than those without mutations (27.6% v 37.4%, P=0.33), although the difference did not reach a significance (Supplementary Table S6 
PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy
The PIK3CA mutation status before and after neoadjuvant chemotherapy in 102 patients in this cohort were assessed. 24 patients of the patients (23.5%) had PIK3CA mutations before neoadjuvant chemotherapy (detailed information on these patients is presented in Table 4 ). After neoadjuvant chemotherapy, of these 24 patients, 15 patients retained their initial PIK3CA mutations (referred to as the mt-mt group), and these 15 patients mainly exhibited luminal subtype (Supplementary table S7); 9 patients lost their initial mutations (referred to as the mt-wt group) ( Table 4 ). The (Fig. 1) . In multivariate analysis, retained the initial mutation remained as a non-significantly unfavorable factor (DFS: adjusted HR=2.27; 95% CI: 0.83-6.25; P=0.11; and DDFS: adjusted HR=1.32; 95% CI: 0.92-1.90; P=0.14) (Supplementary   table S8 ).
Survival
The 5-year DFS and 5-year DDFS rates in the entire study population (n=729) Fig. S2 ).
The association between the PIK3CA mutations and survival in different (Supplementary Fig. S4 ). Among the HER2-positive patients who received trastuzumab treatment, patients with PIK3CA mutations had a tendency towards worse survival than those with wild-type (DFS: unadjusted HR=3.34; 95% CI: 0.61 to 18.27; P=0.14; DDFS: unadjusted HR=4.73; 95% CI: 0.49 to 45.46; P=0.14) (Supplementary Fig. S5 ).
In the TN subgroup, PIK3CA mutant had a significantly worse DFS and (Supplementary Fig. S6 ).
Discussion
To our knowledge, the current study is one of the largest studies to investigate the association between PIK3CA mutations and response to neoadjuvant chemotherapy in breast cancer to date. We found that patients with PIK3CA mutations had a significantly lower pCR rate than those with wild-type. These findings suggested that PIK3CA mutant are resistant to neoadjuvant chemotherapy.
We explored the PIK3CA mutation status in 102 patients before and after neoadjuvant chemotherapy. Patients who retained their initial PIK3CA mutations showed a worse survival than those who lost their initial mutations or those with wild-type. These findings suggested that patients who retained their initial mutations after neoadjuvant chemotherapy harbored an aggressive phenotype and were less sensitive to chemotherapy, therefore, those patients might be suitable for PIK3CA targeted therapy; as one recent study indicated that breast or gynecologic cancer patients with PIK3CA mutations have a higher response to PI3K/AKT/mTOR inhibitors than those with wild-type (11) . On the other hand, patients who lost their initial mutations after neoadjuvant chemotherapy had a favorable outcome and benefited from neoadjuvant chemotherapy. The three hotspot mutations (E542/E545, H1047) accounted for the majority of mutations of the PIK3CA gene in the current study. The mechanisms that activate the PI3K/AKT pathway may be different between the E542/E545 mutations and the H1047 mutation (13-17,23, 24 ). Janku et al recently reported that patients with H1047 mutation are more sensitive to a PI3K/AKT/mTOR inhibitor than those with other mutations or patients with wild-type, and patients with H1047 mutation show a trend for a longer progression-free survival than those with other mutations (38, 39) . In our present study, although the E542/E545 and H1047 mutations exhibited a similar efficacy in response to neoadjuvant chemotherapy, patients with H1047 mutation had a non-significantly better survival than those with E542/E545 mutation.
Emerging evidence suggested that PIK3CA mutations have different roles in different subgroups when stratified by ER, PR and HER2 status (25, 29, 40, 41) . We found that the frequency of PIK3CA mutations was higher for luminal subgroup compared with the HER2+ and TN subgroups, and this observation is consistent with those of previous studies (24, 26) . PIK3CA mutations were significantly associated with a lower pCR rate in the luminal subgroup; whereas PIK3CA mutations were associated with a lower pCR rate in the TN subgroup although the difference was not significant. PIK3CA mutations were not associated with pathologic response among the HER2+ patients treated with neoadjuvant chemotherapy without trastuzumab. Our results suggested that the association between mutated PIK3CA and a reduced pCR rate is dependent on the molecular types, and the association is more pronounced in the luminal subgroup. In contrast, the HER2+ patients treated with neoadjuvant chemotherapy in combination with trastuzumab, we found that patients with PIK3CA mutations had a lower pCR rate than those with wild-type. Interestingly, two recent studies have demonstrated that HER2-positive breast cancer patients with PIK3CA mutations are less likely to achieve a pCR compared with those with wild-type when the patients treated with neoadjuvant chemotherapy plus anti-HER2 therapies in the GeparQuattro, GeparQuinto, and GeparSixto Trials (19) and the NeoATTO trial (35) . Similarly, PIK3CA mutation is associated with a shorter progression-free survival in HER2-positive metastatic breast cancer treated with HER2-targeted therapies in CLEOPATRA trial (42) . Our present observation is in agreement with these findings.
However, unlike the results observed in the neoadjuvant and metastatic settings, there is no association between the PIK3CA mutation and the degree of benefit from transtuzumab in adjuvant setting in the NSABP B-31 trial (43).
Although patients with PIK3CA mutations had a slightly poorer DFS and DDFS than those with wild-type in the entire study population (n=729), the differences did not reach a significance. However, PIK3CA mutations were associated with worse DFS in the TN subgroup. Due to the relatively small sample size of the TN subgroup (n=128), further independent studies are warranted to confirm this observation.
There are two limitations to our study. Although the overall cohort was large, the number of patients who had matched tumor tissues before and after neoadjuvant chemotherapy was not large (n=102), in particular, the PIK3CA mutant in this group 
were relatively small; the current study was retrospective, and the neoadjuvant chemotherapy regimens were not assigned at randomized. Therefore, caution is required when interpreting our results.
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